Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

NCT02301624 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Generalized Myasthenia Gravis

Interventions

BIOLOGICAL: Eculizumab
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.